SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending with retail traders actively discussing price targets and potential for a short squeeze. Despite recent earnings and raised guidance, some express concern over market conditions and volatility. Optimistic investors point to institutional ownership, AI momentum, and potential government reopening as catalysts for a rebound.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending amid discussions about its strategic acquisition of Sentrycs, a counter-drone technology company, and its potential impact on revenue. Community members are debating the company's valuation and growth prospects within the defense and security sectors, as well as upcoming earnings and the potential for government contracts.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid community discussions about potential rallies and long-term holding strategies, with some mentioning a recent ETF filing including SHIB. Despite mixed sentiment, some traders express optimism, while others remain skeptical about its future performance and potential for new all time highs. Community members highlight both bullish and bearish outlooks, and reference the broader meme coin sector.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as investors flock to privacy coins, with community members discussing its potential to reach $1,000 and comparing it to Bitcoin's early days. A recent Coindesk article has added fuel to the fire, while some traders are pointing to a pullback. The coin's limited supply and focus on shielded transactions are key talking points.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk Corp. is trending due to optimism around its potential in the inference market and high-bandwidth flash memory, with community members drawing comparisons to past high-growth tech stories. Despite some bearish sentiment focused on profitability, bullish traders are pointing to future earnings estimates and significant volume spikes as potential catalysts. The stock's parabolic year-to-date performance and analyst upgrades are fueling FOMO, while others caution about overvaluation and potential manipulation.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as the community anticipates upcoming news and potential catalysts, particularly related to its pharmaceutical and battery technology ventures. Discussions revolve around the potential impact of the overfunded pension plan and the possibility of new partnerships or contracts. Some investors are drawing parallels to past meme stock rallies, while others highlight the company's undervalued status.

Peanut the Squirrel Markets

Peanut the Squirrel Markets ($PNUT) is surging, driven by community enthusiasm and speculative momentum reminiscent of other meme coins. Community members are actively discussing potential price targets and noting high trading volume, with some drawing comparisons to established meme coins and anticipating further gains. The coin's recent price action and increased visibility are fueling the current buzz.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy`s Co

Wendy's ($WEN) is trending as community members discuss its recent earnings beat and subsequent stock reversal, closing lower despite initial gains. Investors are weighing the impact of store closures and a turnaround plan amidst leadership uncertainty, while some speculate on the potential for a short squeeze or buyout.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer's stock is active amid an ongoing bidding war with Novo Nordisk for Metsera, a company focused on obesity drugs, with Pfizer filing lawsuits to challenge Novo's acquisition. The community is discussing the implications of this battle, Pfizer's overall strategy in the weight loss market, and whether the company is overpaying for potential acquisitions. Additionally, the stock's dividend and recent earnings are focal points of conversation.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as discussions revolve around the potential impact of the ongoing bidding war with Pfizer for Metsera, and speculation about an upcoming announcement from the Trump administration regarding drug pricing. Community sentiment is mixed, with some investors expressing frustration over the stock's recent performance, while others remain optimistic about the company's long-term prospects and potential catalysts like oral Wegovy approval and broader market access.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on...

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent...

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit

Futures Flat Ahead Of Retail Sales, Trump-Putin Summit US equity futures are slightly higher , hovering near all time highs as traders bet that data on Friday will bolster the case for interest rate...

Precigen, Inc. (PGEN) said on Friday that the US Food and Drug Administration (FDA) has approved its immunotherapy Papzimeos for the treatment of adults with recurrent respiratory papillomatosis (RRP).Recurrent respiratory papillomatosis (RRP) is a rare condition where benign, wart-like tumors, called papillomas, grow in the respiratory tract, most commonly the larynx or the voice box. The disease can lead to severe voice disturbance, a compromised airway, and recurrent post-obstructive pneumonias. According to Precigen, there are about 27,000 adult RRP patients in the U.S.Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with RRP, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/precigen-announces-full-fda-approval-of-papzimeos-zopapogene-imadenovec-drba-the-first-and-only-approved-therapy-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis-302530957.html">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PGEN">Precigen</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. Shares of the company traded 50% higher in the pre-market session at the time of writing.“With the landmark FDA approval of Papzimeos and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," said CEO Helen Sabzevari. Management of RRP, the company said, previously primarily consisted of repeated surgeries that did not address its root cause.The FDA approval was supported by data from an open-label, single-arm study in adult patients with RRP in which 51% of study patients required no surgeries in the 12 months after treatment with Papzimeos. Further, the therapy was well-tolerated in the trial with no serious treatment-related adverse events.Precigen noted that no confirmatory clinical trial is required for the therapy, which is delivered via four subcutaneous injections over a 12-week interval. The company added that it will begin promoting Pazimeos immediately.H.C. Wainwright subsequently raised its price target on Precigen to $8.50 from $6 while keeping a 'Buy' rating on the shares. The firm expects the drug to generate sales of $1.1 billion in 2033 from $138 million in 2026.PGEN stock is up by 65% this year and by about 73% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-climbs-premarket-even-after-warren-buffett-s-berkshire-trims-stake/chsPjsBRdf9">Apple Stock Climbs Premarket Even After Warren Buffett’s Berkshire Trims Stake</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why

The company stated that Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. 

Equity

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 FDA Grants...

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at...

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 9, 2025 GERMANTOWN...

Small-cap, clinical-stage biopharma Precigen, Inc. ($PGEN) rallied on Monday following a regulatory update. The stock ended the session 28.47% higher at $0.9331 on more than six times the average volume.Germantown, Maryland-based Precigen announced the completion of the rolling submission for a biologic license application (BLA) for PRGN-2012, a gene therapy being investigated as a treatment option for adult patients with recurrent respiratory papillomatosis (RRP).RRP is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx, and it is caused by the human papillomavirus (HPV) 6 or HPV 11. It can prove fatal.&nbsp;Precigen said the BLA is now in the initial 60-day review period and the FDA will decide whether to accept the application for further review and set the Prescription Drug User Fee Act (PDUFA) date by this period.The company also noted that the application included a request for priority review, which, if granted, will reduce the review period from 10 months to six months.PRGN-2012 acts by eliciting immune responses directed against cells infected with HPV 6 or HPV 11. The company noted that there is no cure for the condition currently and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease.&nbsp;The regulatory application is supported by pivotal Phase 1/2 study results, which showed more than 50% of patients achieved complete response and more than 85% had a decrease in surgical interventions the year after the treatment.&nbsp;Helen Sabzevari, President and CEO of Precigen, "We look forward to working closely with the FDA on next steps now that we have completed the BLA submission and we are excited by the potential to bring PRGN-2012 to RRP patients as quickly as possible."'The executive also said, with the recent $79 million private placement of convertible preferred stock, the company has extended its cash runway into 2026, well beyond the potential commercial launch in the second half of 2025.<figure class="image"><img style="aspect-ratio:637/135;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/pgen_sentiment_0fbe6731dd.png" alt="pgen-sentiment.png" width="637" height="135"><figcaption>PGEN sentiment and message volume December 31, 2024, as of 3:36 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, sentiment toward Precigen flipped from ‘extremely bearish’ a day ago to ‘extremely bullish’ (96/100), the highest in a year. Message volume also spurted from ‘normal’ to ‘extremely high.’In a message posted on the PGEN stream on Stocktwits, a user said they looked ahead to a good 2025 for the company.&nbsp;<stembedurl>https://stocktwits.com/ASTAD13/message/598217372</stembedurl>If the company manages to get a priority voucher, it can resell it for $100 million, another noted.<stembedurl>https://stocktwits.com/Johnmtnb2018/message/598207700</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/analyst-picks-pegasystems-stock-among-top-10-tech-winners-of-2025/cJO1z97Rkm">Analyst Picks Pegasystems Stock Among Predicted Top 10 Tech Winners Of 2025: Retail Shares The Optimism</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally

Recurrent respiratory papillomatosis is a rare condition when benign tumors called papillomas grow in the respiratory tract, most commonly in the larynx.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

PGEN
Precigen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PGEN News

PGENPrecigen Inc